Emerging therapeutic targets for synovial sarcoma

References

• Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. IARC Press; Lyon, France: 2002
   Google Scholar
• Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011;6(8):e20294
   PubMed Web of Science ®Google Scholar
• Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012;21:333-47
   PubMed Web of Science ®Google Scholar
• Blay JY, Blomqvist C, Bonvalot S, et al. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii92-9
   PubMedGoogle Scholar
• Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007;25:1003-8
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009;115(13):2988-98
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007;246:105-13
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Dall’Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer 2012;48(18):3448-55
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009;115(15):3537-47
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008;112:1585-91
   PubMed Web of Science ®Google Scholar
• Stanelle EJ, Christison-Lagay ER, Wolden SL, et al. Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review. J Pediatr Surg 2013;48(4):757-63
   PubMed Web of Science ®Google Scholar
• Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004;22:4040-50
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004;101:627-34
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010;46(1):72-83
   PubMed Web of Science ®Google Scholar
• Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994;73:2506-11
   PubMed Web of Science ®Google Scholar
• Lee SH, Chang MH, Baek KK, et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. Oncology 2011;80:257-61
   PubMed Web of Science ®Google Scholar
• Salah S, Yaser S, Salem A, et al. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen. Med Oncol 2013;30(3):639
   PubMed Web of Science ®Google Scholar
• Riedel RF. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type? Semin Oncol 2011;38(Suppl 3):S30-42
   Google Scholar
• Casali PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol 2012;23(Suppl 10):x167-9
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999;253:117-30
   PubMed Web of Science ®Google Scholar
• Lammli J, Fan M, Rosenthal HG, et al. Expression of vascular endothe-lial growth factor correlates with the advance of clinical osteosarcoma. Int Orthop 2012;36(11):2307-13
   PubMed Web of Science ®Google Scholar
• Chao C, Al-Saleem T, Brooks JJ, et al. Vascular endothelial growth factor and soft tissue sarcomas:tumor expression correlates with grade. Ann Surg Oncol 2001;8(3):260-7
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti AK, Foster H, et al. Immunohistochemical detectionof HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res 2004;24(1):333-7
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti AK, Tendulkar K, et al. Determination of vascularendothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 2004;130(1):52-60
   PubMed Web of Science ®Google Scholar
• Miettinen M, Rikala MS, Rys J, et al. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol 2012;36(4):629-39
   PubMed Web of Science ®Google Scholar
• Ho AL, Vasudeva SD, Laé M, et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012;72(17):4515-25
   PubMed Web of Science ®Google Scholar
• Peng CL, Guo W, Ji T, et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 2009;8(18):1729-36
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogenactivated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2008;7(4):890-6
   PubMed Web of Science ®Google Scholar
• Maruwge W, D’Arcy P, Folin A, et al. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther 2008;1:67-78
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2008;8:118
   Web of Science ®Google Scholar
• Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 2011;29(3):481-8
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23(2):508-16
   PubMed Web of Science ®Google Scholar
• Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27(19):3133-40
   PubMed Web of Science ®Google Scholar
• Basso U, Brunello A, Bertuzzi A, Santoro A. Sorafenib is active on lung metastases from synovial sarcoma.Ann Oncol. 2009;20(2):386-7
   Google Scholar
• Santoro A, Comandone A, Basso U, et al. A. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. Ann Oncol 2013;24(4):1093-8
   PubMed Web of Science ®Google Scholar
• Vincent P, Zhang X, Chen C, et al. Chemotherapy with the raf kinase inhibitor BAY 43–9006 in combination with irinotecan, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenograft models. Abstract 1900 Proc Am Soc Clin Oncol 2002;21:23b
   Google Scholar
• Martín-Liberal J, López-Pousa A, Broto JM, et al. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs 2014;32(2):287-94
   PubMed Web of Science ®Google Scholar
• Phase I-II Trial of Sorafenib in combination with ifosfamide in soft tissue sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00541840
   Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: Am phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86
   PubMed Web of Science ®Google Scholar
• Pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01446809
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-60
   PubMed Web of Science ®Google Scholar
• Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010;28(35):5174-81
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-50
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Available from: www.ema.europa.eu/ema/index
   Google Scholar
• Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008;19:807-13
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-42
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012;23(3):785-90
   PubMed Web of Science ®Google Scholar
• Gemcitabine and docetaxel with bevacizumab in selected sarcoma subtypes. Available from: http://clinicaltrials.gov/ct2/show/NCT00887809
   Google Scholar
• Phase II study of doxorubicin and Avastin® in sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00755261
   Google Scholar
• Therapeutic trial for patients with ewing sarcoma family of tumor and desmoplastic small round cell tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT01946529
   Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8
   PubMed Web of Science ®Google Scholar
• Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12
   PubMed Web of Science ®Google Scholar
• Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-86
   PubMed Web of Science ®Google Scholar
• Dorkin TJ, Robson CN, Neal DE. The molecular pathology of urological malignancies. J Pathol 1997;183:380-7
   PubMed Web of Science ®Google Scholar
• Nemoto T, Ohashi K, Akashi T, et al. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997;65:195-203
   PubMed Web of Science ®Google Scholar
• Gusterson B, Cowley G, McIlhinney J, et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer 1985;36:689-93
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005;103(4):830-8
   PubMed Web of Science ®Google Scholar
• Nielsen TO, West RB, Linn SC, et al. Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, O’Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003;163:1449-56
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361(10):958-67
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008;13(4):467-73
   PubMed Web of Science ®Google Scholar
• Ha HT, Griffith KA, Zalupski MM, et al. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma. Am J Clin Oncol 2013;36(1):77-82
   PubMed Web of Science ®Google Scholar
• Weigel B, Malempati S, Reid JM, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2014;61(3):452-6
   PubMed Web of Science ®Google Scholar
• Tawbi H, Thomas D, Lucas DR, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 2008;13(4):459-66
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-61
   PubMed Web of Science ®Google Scholar
• Zhou D, Battifora H, Yokota J, et al. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 1987;47:6123-5
   PubMed Web of Science ®Google Scholar
• Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6
   PubMed Web of Science ®Google Scholar
• Allander SV, Illei PB, Chen Y, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161(5):1587-95
   PubMed Web of Science ®Google Scholar
• Nuciforo PG, Pellegrini C, Fasani R, et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol 2003;34:639-45
   PubMed Web of Science ®Google Scholar
• George E, Niehans GA, Swanson PE, et al. Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation. Arch Pathol Lab Med 1992;116:1033-5
   PubMed Web of Science ®Google Scholar
• http://clinicaltrials.gov/ct2/show/NCT00104949
   Google Scholar
• Rikhof B, de Jong S, Suurmeijer AJ, et al. The insulin-like growth factor system and sarcomas. J Pathol 2009;217(4):469-82
   PubMed Web of Science ®Google Scholar
• LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37
   PubMed Web of Science ®Google Scholar
• Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86
   PubMed Web of Science ®Google Scholar
• Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors:new twists in the tale. Nat Rev Mol Cell Biol 2003;4:202-12
   PubMed Web of Science ®Google Scholar
• Devi GR, de Souza AT, Byrd JC, et al. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Res 1999;59:4314-19
   PubMed Web of Science ®Google Scholar
• Wise TL, Pravtcheva DD. Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res 2006;66:1327-36
   PubMed Web of Science ®Google Scholar
• Sun Y, Gao D, Liu Y, et al. IGF2is critical for tumorigenesis by synovial sarcoma oncoprotein SYT–SSX1. Oncogene 2006;25:1042-52
   PubMed Web of Science ®Google Scholar
• De Bruijn DR, Allander SV, Van Dijk AH, et al. The synovial-sarcoma associated SS18–SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006;66:9474-82
   PubMed Web of Science ®Google Scholar
• Tornkvist M, Natalishvili N, Xie Y, et al. Differential roles of SS18–SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun 2008;368:793-800
   PubMed Web of Science ®Google Scholar
• Xie Y, Skytting B, Nilsson G, et al. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999;59:3588-91
   PubMed Web of Science ®Google Scholar
• Friedrichs N, Trautmann M, Endl E, et al. Phosphatidylinositol-3’-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011;129:1564-75
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11(2):129-35
   PubMed Web of Science ®Google Scholar
• Schöffski P, Adkins D, Blay JY, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 2013;49(15):3219-28
   PubMed Web of Science ®Google Scholar
• A Five-tier, open-label study of IMC-A12 in advanced sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00668148
   Google Scholar
• Cixutumumab and doxorubicin hydrochloride in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00720174
   Google Scholar
• Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013;14(4):371-82
   PubMed Web of Science ®Google Scholar
• Setsu N, Kohashi K, Fushimi F, et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Cancer 2013;119(19):3504-13
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012;30(1):78-84
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31(19):2485-92
   PubMed Web of Science ®Google Scholar
• Everolimus in combination with imatinib mesylate in treating patients with locally advanced, locally recurrent, or metastatic soft tissue sarcoma. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01281865
   Google Scholar
• Schuetze SM, Zhao L, Chugh R, et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 2012;48:1347-53
   PubMedGoogle Scholar
• Neghandhi AM, Milhem MM. A combination of sorafenib, nelfinavir, and sirolimus in a patient with progressive metastatic synovial sarcoma after chemotherapy. J Clin Oncol 2011;29(suppl):abstr e20531
   Google Scholar
• A Phase II trial of combined hydroxychloroquine and sirolimus in drug refractory advanced sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01842594
   Google Scholar
• Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 2011;117(15):3468-75
   PubMed Web of Science ®Google Scholar
• Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013;49(1):219-30
   PubMed Web of Science ®Google Scholar
• Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005;11:1835-41
   PubMed Web of Science ®Google Scholar
• Yopp AC, Shia J, Butte JM, et al. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2012;19(Suppl 3):S339-46
   Web of Science ®Google Scholar
• Palmerini E, Benassi MS, Benini S, et al. Synovial sarcoma: is chemotaxis important to tumor progression? JCO Proc ASCO 2013(supp):Abstract 10571
   Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol 2009;27(28):4767-73
   PubMed Web of Science ®Google Scholar
• Uy GL, Rettig MP, Motabi IH, et al. A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119(17):3917-24
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Hirte HW, Moretto P, et al. Final results of a phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Eur J Cancer 2008;6:127
   Web of Science ®Google Scholar
• Wakamatsu T, Naka N, Sasagawa S, et al. VEGF signal axis is a potential therapeutic moleculat target for synovial sarcoma. Abstract 151 CTOS Annual Meeting; 2013
   Google Scholar
• Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 2012;25(6):854-8
   PubMed Web of Science ®Google Scholar
• Pollack SM, Loggers ET, Rodler ET, et al. Immune-based therapies for sarcoma. Sarcoma 2011;438940
   PubMedGoogle Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917-24
   PubMed Web of Science ®Google Scholar
• A pilot study of genetically engineered NY-ESO-1 specific (c259) T cells in HLA-A2+ patients with synovial sarcoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01343043
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. “Improved survival with ipilimumab in patients with metastatic melanoma,”. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013;2013:168145
   PubMedGoogle Scholar
• Gupta A, Nuber N, Esslinger C, et al. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immun 2013;13:3
   PubMedGoogle Scholar
• Rota R, Ciarapica R, Miele L, Locatelli F. Notch signaling in pediatric soft tissue sarcomas. BMC Med 2012;10:141
   PubMed Web of Science ®Google Scholar
• Kelleher FC, Cain JE, Healy JM, et al. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther 2012;136(2):153-68
   PubMed Web of Science ®Google Scholar
• Francis P, Namlos HM, Muller C, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73
   PubMed Web of Science ®Google Scholar
• Wagner A, Hohenberger P, Okuno S, et al. Results from a phase 2 randomized placebo-controlled, double blind study of the hedgehog pathway antagonist IPI-926 in patients with advanced chondrosarcoma. Abstract 015 CTOS Annual Meeting; 2013
   Google Scholar
• Garcia CB, Shaffer CM, Alfaro MP, et al. Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT–SSX2. Oncogene 2012;31(18):2323-34
   PubMed Web of Science ®Google Scholar
• Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated withthe Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 2014;70(1):60-9
   PubMed Web of Science ®Google Scholar
• Copeland RA. Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res 2013;19(23):6344-50
   PubMed Web of Science ®Google Scholar
• Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012;21(3):333-47
   PubMed Web of Science ®Google Scholar
• Study on efficacy and tolerability of vorinostat in patients with advanced, metastatic soft tissue sarcoma (STS) (SAHA-I). Available from: http://clinicaltrials.gov/ct2/show/NCT00918489
   Google Scholar
• Phase 1b/2 study of vorinostat in combination with gemcitabine and docetaxel in advanced sarcoma (GemTax). Available from: http://clinicaltrials.gov/ct2/show/NCT01879085
   Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
   PubMed Web of Science ®Google Scholar